Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 8/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24423092 | 1.00 | CFTR (0.37) | CFTRKDM5APOLBSPRMGLL | |
| SCHEMBL24423984 | 1.00 | CFTR (0.37) | CFTRKDM5APOLBSPRMGLL | |
| SCHEMBL29584668 | 1.00 | CFTR (0.37) | CFTRKDM5APOLBSPRMGLL | |
| SCHEMBL24424213 | 0.88 | CYP4F2 (0.38) | CFTRKDM5AAKR1C3TLR9TLR8 | |
| SCHEMBL30298765 | 0.88 | CYP4F2 (0.38) | CFTRKDM5AAKR1C3TLR9TLR8 | |
| SCHEMBL29243764 | 0.88 | CYP4F2 (0.38) | CFTRKDM5AAKR1C3TLR9TLR8 | |
| SCHEMBL29584356 | 0.88 | CYP4F2 (0.38) | CFTRKDM5AAKR1C3TLR9TLR8 | |
| SCHEMBL24423068 | 0.86 | MGLL (0.39) | CFTRMGLL | |
| SCHEMBL24423081 | 0.86 | MGLL (0.39) | CFTRMGLL | |
| SCHEMBL24423091 | 0.86 | MGLL (0.39) | CFTRMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |